Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Inpefa (sotagliflozin) is an oral dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus and other cardiovascular risk factors. Unlike selective SGLT2 inhibitors, sotagliflozin inhibits both intestinal SGLT1 and renal SGLT2, reducing both postprandial glucose absorption and renal glucose reabsorption. Its cardiometabolic benefits are attributed to mechanisms including natriuresis, improved myocardial energy utilization, and reductions in preload and afterload.
| F act Table | |
| Formula | C21H23FO5S |
| License | US FDA (approved 2023) |
| Bioavailability | ~60% (oral) |
| Legal status | Prescription only (Rx-only) |
| Chemical Name | Sotagliflozin |
| Elimination half-life | 13–16 hours |
| Dosage (Strength) | 200 mg and 400 mg tablets (oral, once daily) |
| Pregnancy | Not recommended during pregnancy |
| Brands | Inpefa |
| Protein binding | >98% |
| PubChem CID | 24812715 |
| MedlinePlus | a622049 |
| ChEBI | 142242 |
| ATC code | C10BK04 |
| DrugBank | DB12020 |
| KEGG | D11219 |
| Routes of administration | Oral |
The recommended starting dose of Inpefa is 200 mg orally once daily. Based on individual response and tolerability, the dose may be increased to 400 mg once daily. It can be taken with or without food. Inpefa should not be initiated in patients with an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m². Renal function should be assessed prior to initiation and periodically thereafter.
Dose adjustments may be required in patients at risk for volume depletion, and diuretic therapy may need to be modified. Therapy should be temporarily discontinued in patients undergoing surgery or experiencing acute illness associated with dehydration or hypotension.
Each Inpefa tablet contains either 200 mg or 400 mg of sotagliflozin. Inactive ingredients include microcrystalline cellulose, magnesium stearate, sodium starch glycolate, mannitol, and colloidal silicon dioxide. The film coating contains hypromellose, titanium dioxide, and polyethylene glycol.
Inpefa is contraindicated in patients with type 1 diabetes mellitus, due to the increased risk of diabetic ketoacidosis (DKA), and in patients on dialysis. It is also contraindicated in those with a history of serious hypersensitivity to sotagliflozin or any component of the formulation.
Inpefa may increase the risk of volume depletion, hypotension, and acute kidney injury, particularly in elderly patients or those on diuretics. It can cause ketoacidosis, including in patients with type 2 diabetes under certain conditions (e.g., during acute illness, surgery, or reduced caloric intake). Monitor for signs of ketoacidosis regardless of blood glucose levels.
Urinary tract infections and genital mycotic infections have been reported. Necrotizing fasciitis of the perineum (Fournier’s gangrene) is a rare but serious adverse event. Use with caution in patients with a history of urinary or genital infections. Discontinue immediately if Fournier’s gangrene is suspected.
Common and serious side effects associated with Inpefa include:
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews